Commercial

Gilead names remdesivir price
Gilead names remdesivir price
Alison Kanski
June 29, 2020
1:42 pm

The treatment will cost $3,120 for a five-day treatment course for a patient with private insurance in the U.S.

Half year pro ad report 2019: Glaxo, J&J and Pfizer topped the list of biggest individual spenders
Half year pro ad report 2019: Glaxo, J&J and Pfizer topped the list of biggest individual spenders
MM+M Staff
October 4, 2019
5:00 am

Marketers of cancer drugs spent far more than marketers of drugs for other conditions.

Pro ad report 2018: Advertising remained flat year over year
Pro ad report 2018: Advertising remained flat year over year
MM+M Staff
March 7, 2019
5:00 am

While advertising in medical journals remained basically flat, the biggest players increased their volume of ad pages.

Drug marketing’s collision course with pricing
Drug marketing’s collision course with pricing
Marc Iskowitz
February 28, 2019
5:00 am

A combination of profound skepticism of the industry and generous funding for health communications is a perfect storm. Is there a way through?

Clarity in DTC TV ad drug pricing
Clarity in DTC TV ad drug pricing
Belle Frank
February 8, 2019
6:00 am

Belle Frank is chief strategy officer, global health practice at VMLY&R.

Co-pay accumulators: A force to be reckoned with in 2019
Co-pay accumulators: A force to be reckoned with in 2019
Laura Entis
January 8, 2019
6:00 am

Experts predict the controversial tactic will be deployed far more widely this year, significantly impacting manufacturers — and, whether or not they realize it yet, patients.

Focus on drugs’ cost may prevent their discovery
Focus on drugs’ cost may prevent their discovery
Sander Flaum
December 5, 2018
7:00 am

Breakthrough drugs will eventually be more affordable, but a misplaced focus on their cost may prevent them from being discovered at all.

PhRMA spent nearly 10 times 2016’s sum on advertising last year
PhRMA spent nearly 10 times 2016’s sum on advertising last year
Alison Kanski
November 26, 2018
10:45 am

The group’s lobbying spend also doubled in 2017 as the Trump administration bore down on drug prices.

CEO: Marketing plan for anti-epileptic aims to distinguish it from sea of other cannabis drugs
CEO: Marketing plan for anti-epileptic aims to distinguish it from sea of other cannabis drugs
Laura Entis
October 26, 2018
10:16 am

A central component of the Epidiolex marketing strategy involves highlighting the drug’s efficacy and safety profile, not its precedent-setting CBD component.

Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
Laura Entis
October 17, 2018
5:00 am

The war on cancer took a big turn with the birth of checkpoint inhibitors. Laura Entis explores their scientific and commercial impact, the unanswered questions, and what’s next for this enormously successful group of immunotherapies.

  • From Our Partners